An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors
An Open-Label, Multicenter, Expanded Access Program for Emicizumab in Patients With Hemophilia A With Inhibitors
Sponsor: Genentech, Inc.
This observational or N/A phase trial investigates Hemophilia A and is currently ongoing. Genentech, Inc. leads this study, which shows 7 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Approved For Marketing
-
Jul 2024 — Sep 2024 [monthly]
Approved For Marketing
-
Jan 2021 — Jul 2024 [monthly]
Approved For Marketing
-
Jun 2018 — Jan 2021 [monthly]
Approved For Marketing
-
Apr 2018 — Jun 2018 [monthly]
Approved For Marketing
Status: Available → Approved For Marketing · Phase: NA → None
▶ Show 2 earlier versions
-
Aug 2017 — Apr 2018 [monthly]
Available NA
-
Jun 2017 — Aug 2017 [monthly]
Available NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Genentech, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .